Product image of Metronidazol Basi (Metronidazole) supplied by GNH India

Metronidazol Basi

Active Ingredient:
Metronidazole
Origin:
EU

Metronidazol Basi (Metronidazole)

Metronidazole, the active ingredient in Metronidazol Basi, is a nitroimidazole presented as an intravenous solution for parenteral use. It treats a range of anaerobic bacterial and protozoal infections in adult patients.
GNH India supplies Metronidazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratórios Basi – Indústria Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metronidazol Basi, a nitroimidazole, is employed against infections caused by anaerobic bacteria and certain protozoa.

  • Anaerobic bacterial infections: effective in reducing bacterial load in intra‑abdominal, pelvic and soft‑tissue infections.
  • Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes.
  • Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission.
  • Amoebiasis: treats intestinal and extra‑intestinal infections caused by Entamoeba histolytica.
  • Clostridioides difficile infection: suppresses toxin‑producing C. difficile strains in moderate to severe cases.

How It Works

  • Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to loss of cell viability and bacterial or protozoal death. The selective activation in low‑oxygen environments provides targeted antimicrobial activity while sparing most aerobic host cells.

Side Effects

Metronidazol Basi may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Metallic taste: transient metallic sensation in the mouth.
  • Headache: occasional dull or throbbing pain.
  • Diarrhoea: loose stools that may be watery.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Dizziness: light‑headed feeling, especially on standing.

Serious or Rare Side Effects

  • Seizures: rare neurologic events requiring immediate care.
  • Peripheral neuropathy: tingling or numbness in extremities.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Stevens‑Johnson syndrome: serious skin and mucous membrane disorder.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Neutropenia: marked reduction in white blood cells.

Precautions & Warnings

Before using Metronidazol Basi, consider the following safety measures.

  • Renal function: adjust or monitor in patients with severe renal impairment.
  • Hepatic function: use cautiously in individuals with liver disease.
  • Alcohol consumption: avoid alcohol during therapy and for at least 48 hours after the last dose to prevent a disulfiram‑like reaction.
  • Pregnancy: safety not established; weigh potential benefits against risks.
  • Concomitant medications: review for possible interactions, especially anticoagulants and neurotoxic agents.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Metronidazol Basi can interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Alcohol: may cause severe flushing, tachycardia, and hypotension.
  • Warfarin: potentiates anticoagulant effect, increasing bleeding risk.
  • Lithium: can raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely)

  • Phenytoin: may reduce metronidazole plasma levels, decreasing efficacy.
  • Phenobarbital: can lower drug concentrations through enzyme induction.
  • Erythromycin: may increase metronidazole levels, requiring dose adjustment.

Frequently Asked Questions

Metronidazol Basi is indicated for infections caused by anaerobic bacteria and certain protozoa, including intra‑abdominal and pelvic infections, bacterial vaginosis, trichomoniasis, amoebiasis, and moderate to severe Clostridioides difficile infection.

Metronidazole enters anaerobic microorganisms and is reduced to nitro radicals that damage DNA and inhibit nucleic acid synthesis. This selective activation leads to microbial cell death while sparing most aerobic human cells.

The exact dose and duration are set by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and local treatment guidelines. No universal dosing regimen is provided here.

The pregnancy category for metronidazole is not definitively established. Use is generally avoided in the first trimester and only considered when the potential benefit outweighs the risk. Limited data are available for breastfeeding, so clinicians should assess risk versus benefit.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazole is a nitroimidazole with broad activity against anaerobes and certain protozoa, often preferred for its oral and intravenous formulations. Alternatives such as clindamycin or carbapenems may be used, but metronidazole typically offers a favorable safety profile, lower cost, and specific efficacy against protozoal infections.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and light. Do not freeze. Inspect the container for any signs of damage before use and follow aseptic techniques when preparing the intravenous solution.

Metronidazol Basi is given by intravenous infusion. The infusion rate and dilution volume are determined by the prescribing clinician, who will also monitor the patient for any adverse reactions during and after administration.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, and neutropenia. Patients should be monitored closely for neurological symptoms, skin changes, or signs of liver injury.

Metronidazol Basi is contraindicated in patients with known hypersensitivity to metronidazole or other nitroimidazoles. Caution is also advised for individuals with severe hepatic impairment, those receiving disulfiram, and patients with a history of severe neurologic reactions to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metronidazole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT